Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

AUPH

Aurinia Pharmaceuticals (AUPH)

Aurinia Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AUPH
FechaHoraFuenteTítuloSímboloCompañía
24/09/202407:10Business WireAurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus NephritisNASDAQ:AUPHAurinia Pharmaceuticals Inc
20/09/202415:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AUPHAurinia Pharmaceuticals Inc
13/09/202405:00Business WireAurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
12/09/202415:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUPHAurinia Pharmaceuticals Inc
12/09/202415:05Business WireAurinia Announces Board RestructuringNASDAQ:AUPHAurinia Pharmaceuticals Inc
05/09/202405:00Business WireAurinia Announces First Participant Dosed in AUR200 Single Ascending Dose TrialNASDAQ:AUPHAurinia Pharmaceuticals Inc
28/08/202405:00Business WireAurinia to Participate in H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
01/08/202405:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AUPHAurinia Pharmaceuticals Inc
01/08/202405:00Business WireAurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
19/07/202405:00Business WireAurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
02/07/202405:00Business WireAurinia to Participate in Upcoming Investor Healthcare ConferencesNASDAQ:AUPHAurinia Pharmaceuticals Inc
14/06/202411:16Business WireAurinia Announces 2024 Annual General Meeting ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
05/06/202405:00Business WireAurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
04/06/202416:30Business WireAurinia Addresses Dubious Proposals Put Forth by Lucien SelceNASDAQ:AUPHAurinia Pharmaceuticals Inc
04/06/202416:25Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AUPHAurinia Pharmaceuticals Inc
03/06/202417:30Business WireAurinia Provides Update on Proxy StatementNASDAQ:AUPHAurinia Pharmaceuticals Inc
30/05/202405:00Business WireAurinia Will Attend 2024 Jefferies Global Healthcare ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
14/05/202405:00Business WireAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
09/05/202405:00Business WireAurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
07/05/202405:00Business WireAurinia Will Attend 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
02/05/202405:00Business WireAurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational ResultsNASDAQ:AUPHAurinia Pharmaceuticals Inc
01/05/202405:00Business WireAurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness MonthNASDAQ:AUPHAurinia Pharmaceuticals Inc
30/04/202405:00Business WireThe U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical ProgramNASDAQ:AUPHAurinia Pharmaceuticals Inc
16/04/202409:48Business WireUPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
15/04/202405:00Business WireAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024NASDAQ:AUPHAurinia Pharmaceuticals Inc
09/04/202405:00Business WireAurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:AUPHAurinia Pharmaceuticals Inc
29/02/202407:30Business WireAurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase ProgramNASDAQ:AUPHAurinia Pharmaceuticals Inc
22/02/202415:19Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:AUPHAurinia Pharmaceuticals Inc
15/02/202405:16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AUPHAurinia Pharmaceuticals Inc
15/02/202405:00Business WireAurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder ValueNASDAQ:AUPHAurinia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AUPH

Su Consulta Reciente

Delayed Upgrade Clock